Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bryce Alan H, Crawford E David, Agarwal Neeraj, Hussain Maha H, Beltran Himisha, Cooperberg Matthew R, Petrylak Daniel P, Shore Neal, Spratt Daniel E, Tagawa Scott T, Antonarakis Emmanuel S, Aparicio Ana M, Armstrong Andrew J, Boike Thomas P, Calais Jeremie, Carducci Michael A, Chapin Brian F, Cookson Michael S, Davis John W, Dorff Tanya, Eggener Scott E, Feng Felix Y, Gleave Martin, Higano Celestia, Iagaru Andrei, Morgans Alicia K, Morris Michael, Murray Katie S, Poage Wendy, Rettig Matthew B, Sartor Oliver, Scher Howard I, Sieber Paul, Small Eric, Srinivas Sandy, Yu Evan Y, Zhang Tian, Koo Phillip J
Аннотация
MATERIALS AND METHODS: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators.
RESULTS: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)-positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies.
CONCLUSIONS: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.